BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30679164)

  • 1. Ultrasensitive Immunoprofiling of Plasma Extracellular Vesicles Identifies Syndecan-1 as a Potential Tool for Minimally Invasive Diagnosis of Glioma.
    Indira Chandran V; Welinder C; Månsson AS; Offer S; Freyhult E; Pernemalm M; Lund SM; Pedersen S; Lehtiö J; Marko-Varga G; Johansson MC; Englund E; Sundgren PC; Belting M
    Clin Cancer Res; 2019 May; 25(10):3115-3127. PubMed ID: 30679164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comprehensive Proteomic SWATH-MS Workflow for Profiling Blood Extracellular Vesicles: A New Avenue for Glioma Tumour Surveillance.
    Hallal S; Azimi A; Wei H; Ho N; Lee MYT; Sim HW; Sy J; Shivalingam B; Buckland ME; Alexander-Kaufman KL
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging clinical potential of circulating extracellular vesicles for non-invasive glioma diagnosis and disease monitoring.
    Hallal S; Ebrahimkhani S; Shivalingam B; Graeber MB; Kaufman KL; Buckland ME
    Brain Tumor Pathol; 2019 Apr; 36(2):29-39. PubMed ID: 30859343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of serum extracellular vesicles as noninvasive diagnostic markers of glioma.
    Wang H; Jiang D; Li W; Xiang X; Zhao J; Yu B; Wang C; He Z; Zhu L; Yang Y
    Theranostics; 2019; 9(18):5347-5358. PubMed ID: 31410219
    [No Abstract]   [Full Text] [Related]  

  • 5. Global extracellular vesicle proteomic signature defines U87-MG glioma cell hypoxic status with potential implications for non-invasive diagnostics.
    Indira Chandran V; Welinder C; Gonçalves de Oliveira K; Cerezo-Magaña M; Månsson AS; Johansson MC; Marko-Varga G; Belting M
    J Neurooncol; 2019 Sep; 144(3):477-488. PubMed ID: 31414377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory investigation of eight circulating plasma markers in brain tumor patients.
    Ilhan-Mutlu A; Wagner L; Widhalm G; Wöhrer A; Bartsch S; Czech T; Heinzl H; Leutmezer F; Prayer D; Marosi C; Base W; Preusser M
    Neurosurg Rev; 2013 Jan; 36(1):45-55; discussion 55-6. PubMed ID: 22763625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
    Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
    J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
    Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
    World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep Sequencing of Small RNAs from Neurosurgical Extracellular Vesicles Substantiates miR-486-3p as a Circulating Biomarker that Distinguishes Glioblastoma from Lower-Grade Astrocytoma Patients.
    Hallal S; Ebrahim Khani S; Wei H; Lee MYT; Sim HW; Sy J; Shivalingam B; Buckland ME; Alexander-Kaufman KL
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.
    Szarvas T; Sevcenco S; Módos O; Keresztes D; Nyirády P; Kubik A; Romics M; Kovalszky I; Reis H; Hadaschik B; Shariat SF; Kramer G
    Urol Oncol; 2018 Jun; 36(6):312.e9-312.e15. PubMed ID: 29628317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.
    Regazzo G; Terrenato I; Spagnuolo M; Carosi M; Cognetti G; Cicchillitti L; Sperati F; Villani V; Carapella C; Piaggio G; Pelosi A; Rizzo MG
    J Exp Clin Cancer Res; 2016 Jul; 35(1):124. PubMed ID: 27476114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.
    Szarvas T; Reis H; Vom Dorp F; Tschirdewahn S; Niedworok C; Nyirady P; Schmid KW; Rübben H; Kovalszky I
    Prostate; 2016 Aug; 76(11):977-85. PubMed ID: 27062540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ExRNA in Biofluids as Biomarkers for Brain Tumors.
    Rennert RC; Hochberg FH; Carter BS
    Cell Mol Neurobiol; 2016 Apr; 36(3):353-60. PubMed ID: 26993514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Eighteen Serum Cytokine Signature for Discriminating Glioma from Normal Healthy Individuals.
    Nijaguna MB; Patil V; Hegde AS; Chandramouli BA; Arivazhagan A; Santosh V; Somasundaram K
    PLoS One; 2015; 10(9):e0137524. PubMed ID: 26390214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and low-grade glioma: the emergence of genetic information.
    Claus EB; Walsh KM; Wiencke JK; Molinaro AM; Wiemels JL; Schildkraut JM; Bondy ML; Berger M; Jenkins R; Wrensch M
    Neurosurg Focus; 2015 Jan; 38(1):E6. PubMed ID: 25552286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of systemic immune-inflammation index in the differential diagnosis of high- and low-grade gliomas.
    Liang R; Chen N; Li M; Wang X; Mao Q; Liu Y
    Clin Neurol Neurosurg; 2018 Jan; 164():50-52. PubMed ID: 29175722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma.
    Lan F; Qing Q; Pan Q; Hu M; Yu H; Yue X
    Cell Oncol (Dordr); 2018 Feb; 41(1):25-33. PubMed ID: 29076027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma.
    Ohno M; Matsuzaki J; Kawauchi J; Aoki Y; Miura J; Takizawa S; Kato K; Sakamoto H; Matsushita Y; Takahashi M; Miyakita Y; Ichimura K; Narita Y; Ochiya T
    JAMA Netw Open; 2019 Dec; 2(12):e1916953. PubMed ID: 31808923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.
    Lin Y; Jiang T; Zhou K; Xu L; Chen B; Li G; Qiu X; Jiang T; Zhang W; Song SW
    Neuro Oncol; 2009 Oct; 11(5):468-76. PubMed ID: 19164435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.
    Szarvas T; Reis H; Kramer G; Shariat SF; Vom Dorp F; Tschirdewahn S; Schmid KW; Kovalszky I; Rübben H
    Hum Pathol; 2014 Apr; 45(4):674-82. PubMed ID: 24656090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.